Abstract
Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of the mFOLFOX6 regimen plus bevacizumab. Initially he had an increase in CEA after which the level reduced, suggesting the occurrence of a CEA flare. The patient experienced a good response to therapy. In recent literature, CEA flare was identified as a good predictor of response to first-line chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
